Emergent Health Corp
Emergent Health Corp. develops and sells regenerative medicine, neutraceuticals, and phytonutritionals. Its products comprise Vita-Stim, a nutrient that enhances the immune system, nourishes stem cells, and maintains health; Neuvitale, which nourishes stem cells and acts as a methyl donor to protect DNA; Hungarest, a diet aid that controls appetite in the brain and stomach; EmergentO2, water oxyg… Read more
Emergent Health Corp (EMGE) - Net Assets
Latest net assets as of September 2024: $-3.16 Million USD
Based on the latest financial reports, Emergent Health Corp (EMGE) has net assets worth $-3.16 Million USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($209.16K) and total liabilities ($3.37 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-3.16 Million |
| % of Total Assets | -1510.27% |
| Annual Growth Rate | N/A |
| 5-Year Change | -345.73% |
| 10-Year Change | N/A |
| Growth Volatility | 42911.81 |
Emergent Health Corp - Net Assets Trend (2010–2023)
This chart illustrates how Emergent Health Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Emergent Health Corp (2010–2023)
The table below shows the annual net assets of Emergent Health Corp from 2010 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-2.35 Million | -122.05% |
| 2022-12-31 | $-1.06 Million | -3449.38% |
| 2021-12-31 | $31.63K | -92.10% |
| 2019-12-31 | $400.22K | -58.19% |
| 2013-12-31 | $957.28K | +114372.83% |
| 2012-12-31 | $836.25 | -99.89% |
| 2011-12-31 | $743.63K | +83.97% |
| 2010-12-31 | $404.22K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Emergent Health Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15527.8% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $426.95K | % |
| Other Comprehensive Income | $-426.95K | % |
| Other Components | $2.50 Million | % |
| Total Equity | $-2.44 Million | 100.00% |
Emergent Health Corp Competitors by Market Cap
The table below lists competitors of Emergent Health Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NUWEW
PINK:NUWEW
|
$9.19 |
|
First Republic Corp. of America
PINK:FRPC
|
$9.21 |
|
PRESTIGE ASSURANCE CO. PLC
XNSA:PRESTIGE
|
$9.23 |
|
Postd Merchant Banque
PINK:PMBY
|
$9.23 |
|
Winners Inc
PINK:WNRS
|
$9.04 |
|
All American Gld Crp
PINK:AAGC
|
$8.97 |
|
Fifty 1 Labs, Inc.
PINK:FITY
|
$8.95 |
|
Gemini Group Global Corp
PINK:GMNI
|
$8.87 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Emergent Health Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -1,144,833 to -2,437,926, a change of -1,293,093.
- Net loss of 1,628,073 reduced equity.
- Other comprehensive income decreased equity by 166,100.
- Other factors increased equity by 501,080.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.63 Million | -66.78% |
| Other Comprehensive Income | $-166.10K | -6.81% |
| Other Changes | $501.08K | +20.55% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Emergent Health Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | $0.00 | $0.00 | x |
| 2011-12-31 | $0.00 | $0.00 | x |
| 2012-12-31 | $0.03 | $0.00 | x |
| 2013-12-31 | $0.04 | $0.00 | x |
| 2019-12-31 | $0.01 | $0.00 | x |
| 2020-12-31 | $0.00 | $0.00 | x |
| 2021-12-31 | $0.00 | $0.00 | x |
| 2022-12-31 | $0.00 | $0.00 | x |
| 2023-12-31 | $-0.01 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Emergent Health Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -99.57%
- • Asset Turnover: 3.06x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (2.09%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 11.95% | 20.15% | 0.57x | 1.04x | $7.89K |
| 2011 | 34.09% | 35.85% | 0.67x | 1.42x | $179.10K |
| 2012 | 15.74% | 9.64% | 1.51x | 1.08x | $48.01 |
| 2013 | 12.64% | 12.23% | 0.96x | 1.08x | $25.30K |
| 2019 | -21.68% | -36.86% | 0.45x | 1.30x | $-98.63K |
| 2020 | -33.94% | -47.33% | 0.52x | 1.38x | $-102.44K |
| 2021 | 0.00% | -241.51% | 0.32x | 0.00x | $-283.20K |
| 2022 | 0.00% | -366.76% | 0.73x | 0.00x | $-1.99 Million |
| 2023 | 0.00% | -99.57% | 3.06x | 0.00x | $-1.38 Million |
Industry Comparison
This section compares Emergent Health Corp's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Emergent Health Corp (EMGE) | $-3.16 Million | 11.95% | N/A | $9.14 |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |